Saturday, 17 October 2026European Markets

DGB GROUP N.V. Stock Drops By 22% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of DGB GROUP N.V. (AEX-Index: DGB.AS) dropped by a staggering 22.08% in 10 sessions from €0.77 to €0.60 at 05:08 EST on Thursday, following the last session's downward trend. AEX-Index is dropping 0.38% to €760.22, following the last session's downward trend.

DGB GROUP N.V.'s last close was €0.58, 51.67% below its 52-week high of €1.20.

About DGB GROUP N.V.

DGB Group N.V. invests in, develops, and manages biodiversity and carbon offset projects for businesses and governments in the Netherlands and internationally. The company provides nature-based solutions, as well as focuses on nature conservation activities. It is also involved in the trees breeding and planting business. The company was formerly known as Verenigde Nederlandse Compagnie N.V. and changed its name to DGB Group N.V. in January 2018. DGB Group N.V. was founded in 1957 is based in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, DGB GROUP N.V. has a trailing twelve months EPS of €-0.1.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -19%.

More news about DGB GROUP N.V. (DGB.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com